Key result
Oral administration of ticagrelor, in contrast to clopidogrel and prasugrel, prevented adenosine diphosphate-induced contraction of vascular smooth muscle cells in a rat model.
Why the study?
Does ticagrelor prevent ADP-induced vascular smooth muscle cell contraction compared to clopidogrel, prasugrel, or placebo in Wistar rats?
Population
Wistar rats (n=30)
Comparison
Ticagrelor vs Clopidogrel, prasugrel, or placebo administered…
Design
Preclinical, placebo-controlled
Authors
Loading...
Should not change antiplatelet choice in patients; leaves open whether ticagrelor offers unique vascular benefits in humans.
RCT (n=30)
Does ticagrelor prevent ADP-induced vascular smooth muscle cell contraction compared to clopidogrel, prasugrel, or placebo in Wistar rats?
Ticagrelor, unlike clopidogrel and prasugrel, prevents ADP-induced vascular smooth muscle cell contraction in a rat model, suggesting potential off-target vascular benefits.
Grześk et al. (2012) conducted an RCT in Vascular smooth muscle cell contraction (n=30). Ticagrelor, clopidogrel, and prasugrel vs. Placebo was evaluated on 2-MeS-ADP-induced contraction of vascular smooth muscle cells. Oral administration of ticagrelor, in contrast to clopidogrel and prasugrel, prevented adenosine diphosphate-induced contraction of vascular smooth muscle cells in a rat model.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: